Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...

Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data ...

USA News Group News Commentary ? A growing consensus in artificial intelligence holds that the models themselves are becoming interchangeable, and that durable advantage is migrating away from the ...